News Image

NASDAQ:GMAB is showing good growth, while it is not too expensive.

By Mill Chart

Last update: Feb 29, 2024

Our stock screening tool has pinpointed GENMAB A/S -SP ADR (NASDAQ:GMAB) as a growth stock that isn't overvalued. NASDAQ:GMAB is excelling in various growth indicators while maintaining a solid financial footing. Furthermore, it remains attractively priced. Let's delve into the specifics below.

Growth Analysis for NASDAQ:GMAB

ChartMill assigns a Growth Rating to each stock, ranging from 0 to 10. This rating is determined by analyzing different growth elements, including EPS and revenue growth, spanning both historical and future figures. In the case of NASDAQ:GMAB, the assigned 8 reflects its growth potential:

  • The Earnings Per Share has been growing by 22.70% on average over the past years. This is a very strong growth
  • Looking at the last year, GMAB shows a quite strong growth in Revenue. The Revenue has grown by 12.87% in the last year.
  • GMAB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 40.35% yearly.
  • Based on estimates for the next years, GMAB will show a very strong growth in Earnings Per Share. The EPS will grow by 31.70% on average per year.
  • The Revenue is expected to grow by 18.74% on average over the next years. This is quite good.
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

Exploring NASDAQ:GMAB's Valuation

An integral part of ChartMill's stock analysis is the Valuation Rating, which spans from 0 to 10. This rating evaluates diverse valuation factors, including price to earnings and cash flows, while considering the stock's profitability and growth. NASDAQ:GMAB has received a 7 out of 10:

  • 96.10% of the companies in the same industry are more expensive than GMAB, based on the Price/Earnings ratio.
  • GMAB's Price/Forward Earnings ratio is rather cheap when compared to the industry. GMAB is cheaper than 96.78% of the companies in the same industry.
  • GMAB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GMAB is cheaper than 95.93% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, GMAB is valued cheaply inside the industry as 97.46% of the companies are valued more expensively.
  • GMAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • GMAB has a very decent profitability rating, which may justify a higher PE ratio.
  • GMAB's earnings are expected to grow with 34.79% in the coming years. This may justify a more expensive valuation.

Understanding NASDAQ:GMAB's Health Score

ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NASDAQ:GMAB, the assigned 8 reflects its health status:

  • GMAB has an Altman-Z score of 23.09. This indicates that GMAB is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 23.09, GMAB belongs to the best of the industry, outperforming 92.88% of the companies in the same industry.
  • The Debt to FCF ratio of GMAB is 0.11, which is an excellent value as it means it would take GMAB, only 0.11 years of fcf income to pay off all of its debts.
  • GMAB has a better Debt to FCF ratio (0.11) than 97.12% of its industry peers.
  • GMAB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • GMAB has a Current Ratio of 13.34. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
  • GMAB's Current ratio of 13.34 is amongst the best of the industry. GMAB outperforms 84.41% of its industry peers.
  • A Quick Ratio of 13.32 indicates that GMAB has no problem at all paying its short term obligations.
  • The Quick ratio of GMAB (13.32) is better than 84.41% of its industry peers.

What does the Profitability looks like for NASDAQ:GMAB

ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:GMAB has earned a 7 out of 10:

  • Looking at the Return On Assets, with a value of 12.33%, GMAB belongs to the top of the industry, outperforming 97.97% of the companies in the same industry.
  • The Return On Equity of GMAB (13.77%) is better than 96.78% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 12.63%, GMAB belongs to the top of the industry, outperforming 97.29% of the companies in the same industry.
  • Looking at the Profit Margin, with a value of 26.42%, GMAB belongs to the top of the industry, outperforming 97.80% of the companies in the same industry.
  • GMAB has a Operating Margin of 32.30%. This is amongst the best in the industry. GMAB outperforms 98.47% of its industry peers.
  • GMAB's Gross Margin of 98.63% is amongst the best of the industry. GMAB outperforms 98.31% of its industry peers.

More Affordable Growth stocks can be found in our Affordable Growth screener.

Our latest full fundamental report of GMAB contains the most current fundamental analsysis.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

GENMAB A/S -SP ADR

NASDAQ:GMAB (5/29/2024, 7:06:51 PM)

Premarket: 27.94 -0.05 (-0.18%)

27.99

-0.02 (-0.07%)

GMAB News

News Image7 days ago - Genmab A/SGenmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
News Image9 days ago - Genmab A/SGenmab Completes Acquisition of ProfoundBio
News Image10 days ago - InvestorPlace7 Biotech Stocks That Could Breathe New Life Into Your Portfolio

Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions.

News Image13 days ago - Market News VideoJuly 19th Options Now Available For Genmab (GMAB)
News Image16 days ago - Genmab A/SGenmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
News Imagea month ago - InvestorPlaceGMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024

GMAB stock results show that Genmab beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

News Imagea month ago - Pfizer Inc.FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
News Imagea month ago - Genmab A/STIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
News Imagea month ago - Investor's Business DailyWhy Big Pharma Is Following Novartis' Lead In A $25 Billion Market

The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.

News Image2 months ago - Investor's Business DailyGenmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio

Genmab is buying a privately held company focused on antibody drug conjugates.

News Image2 months ago - Genmab A/SGenmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GMAB Links
Follow us for more